Lactobacillus brevis CD2
Trials 8
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus brevis CD2 | “oral gel containing Streptococcus salivarius K12 (2 billion live bacilli) and Lactobacillus brevis CD2 (4 billion live bacilli)” NCT05175833 ↗8“Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer” PMID 21741230 ↗ Jul 2011 “Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2” NCT02357771 ↗ “Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2” NCT02390687 ↗ “Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.” NCT02203812 ↗ “Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2” NCT02121665 ↗ “Lactobacillus brevis CD2 in lozenges containing 4 billion CFU.” NCT04398511 ↗ |
| Known as | L brevis | “probiotic Lactobacillus brevis CD2 (L brevis) is benefic in this condition.” NCT04398511 ↗ |
| Known as | L. brevis CD2 | “Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2” NCT02357771 ↗2“daily treatment with lozenges containing either L. brevis CD2 or placebo” PMID 21741230 ↗ Jul 2011 “L. brevis CD2 Lozenges” NCT02203812 ↗ |
| Known as | Lactobacillus CD 2 | “Recently investigators have shown effectiveness of a probiotic Lactobacillus CD 2 in reducing incidence and severity of chemo-radiotherapy induced mucositis in head and neck...” NCT01797952 ↗ |
| Modality | Other / unclassified | “It contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient.” NCT01797952 ↗ |
| Route | Oral | “one lozenge to be taken every 2-3 hours preferably not before the meal” NCT01797952 ↗ |